| Bioactivity | Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA[1]. |
| Invitro | In vitro transfection of tivanisiran was shown to produce a 50-60% decrease in TRPV1 mRNA levels[1][2]. |
| Name | Tivanisiran |
| CAS | 1848224-71-4 |
| Sequence | RNA, (A-A-G-C-G-C-A-U-C-U-U-C-U-A-C-U-U-C-A), complex with RNA (U-G-A-A-G-U-A-G-A-A-G-A-U-G-C-G-C-U-U) (1:1) |
| Molar Mass | 12068.30 (AS: 5294.6 + SS: 6125.7) |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
| Reference | [1]. Anne-Marie Bleau, et al. Development of tivanisiran, a topical siRNA designed to [2]. Javier Moreno-Montañés, et al. Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426. |
Tivanisiran
CAS: 1848224-71-4 F: W: 12068.30 (AS: 5294.6 + SS: 6125.7)
Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient re
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.